American Journal of Medical Case Reports
ISSN (Print): 2374-2151 ISSN (Online): 2374-216X Website: http://www.sciepub.com/journal/ajmcr Editor-in-chief: Samy, I. McFarlane
Open Access
Journal Browser
Go
American Journal of Medical Case Reports. 2015, 3(10), 319-321
DOI: 10.12691/ajmcr-3-10-4
Open AccessCase Report

Exceptional Cause of Massive Lymph Node Enlargement: Primary Localized Amyloidosis

Imene Boukhris1, , Samira Azzabi1, Ines kechaou1, Eya Chérif1, Chékib Kooli1, Nédia Znaidi2, Lamia Ben Hassine1 and Narjess Khalfallah1

1Internal Medicine Department, University hospital of Charles Nicolle, Tunis, Tunisia

2Department of Diagnostic Pathology, University hospital of Charles Nicolle, Tunis, Tunisia

Pub. Date: September 07, 2015

Cite this paper:
Imene Boukhris, Samira Azzabi, Ines kechaou, Eya Chérif, Chékib Kooli, Nédia Znaidi, Lamia Ben Hassine and Narjess Khalfallah. Exceptional Cause of Massive Lymph Node Enlargement: Primary Localized Amyloidosis. American Journal of Medical Case Reports. 2015; 3(10):319-321. doi: 10.12691/ajmcr-3-10-4

Abstract

Amyloidosis is very rarely the cause of lymph node enlargement. In the localized form of the disease, amyloidosis commonly attains the bladder, the lung and the skin. Lymph node amyloid deposition is very unusual in the localized form of the disease. In particular, cervical and mediastinal sites are uncommon. We report an exceptional case of primary localized AL amyloidosis presenting as generalized lymph node enlargement. Our patient was initially treated by colchicine but in front of disease progression, a treatment with prednisone and melphalan was necessary for stabilization. Clinician should consider primary amyloidosis in the check-list of etiologies causing lymph node enlargement.

Keywords:
amyloidosis lymphadenopathy Localized

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

Figure of 5

References:

[1]  Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S, et al. Amyloid: toward terminology clarification. Report from the nomenclature committee of the International Society of Amyloidosis. Amyloid 2005; 12: 1-4.
 
[2]  Newland JR, Linke RP, Lennert K. Amyloid deposits in lymph nodes: a morphologic and immunohistochemical study. Hum Pathol 1986; 17: 1245-9.
 
[3]  Sipe JD, Benson MD, Buxbaum JN. Amyloid fibril protein nomenclature: 2012 Recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 2012;19: 167-70.
 
[4]  Kyle RA, Bayrd ED. Amyloidosis: Review of 236 cases. Medicine 1975;54: 271-99.
 
[5]  Seccia V, Dallan I, Cervetti G, Lenzi R, Marchetti M, Casani AP, et al. A rare case of primary systemic amyloidosis of the neck with massive cervical lymph node involvement: a case report and review of the literature. Leuk Res 2010; 34:e100-3.
 
[6]  Palladini G, Russo P, Bosoni T, Sarais G, Lavatelli F, Foli A, et al. AL amyloidosis associated with IgM monoclonal protein: a distinct clinical entity. Clin Lymphoma Myeloma 2009;9: 80-3.
 
[7]  Gertz MA, Lacy MQ, Dispenzieri A, Gastineau DA, Chen MG, Ansell SM, et al. Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med 2002;113: 549-55.
 
[8]  Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicines. N Engl J Med. 1997 Apr 24; 336: 1202-7.
 
[9]  Kumar SK, Gertz MA, Lacy MQ, Dingli D, Hayman SR, Buadi FK, et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc 2011; 86: 12-8.
 
[10]  Penner CR, Muller S. Head and neck amyloidosis: a clinicopathologic study of 15 cases. Oral Oncol 2006; 42: 421-9.